Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Promising activity of KA2237 in R/R B-cell lymphoma

Loretta Nastoupil • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Chronic Lymphocytic Leukemia Follicular Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia KA2237

Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the results of the first-in-human, dose ascending, phase I study (NCT02679196) examining the safety and tolerability of KA2237, an oral inhibitor of the PI3K β and δ isoforms in patients with relapsed/refractory (R/R) B-cell lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Loretta Nastoupil

1:10
NHL: What's hot at ASH 2023?
Loretta Nastoupil • 8 Dec 2023
2:20
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil • 8 Dec 2023
1:48
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
Loretta Nastoupil • 8 Dec 2023
1:51
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil • 8 Dec 2023

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
The content of VJHemOnc is intended for healthcare professionals